Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial
Matthew Van Oirschot, Alanah Bergman, Wilko F.A.R. Verbakel, Lucy Ward, Isabelle Gagne, Vicky Huang, Nick Chng, P. Houston, Kerry Symes, Christopher G. Thomas, Parminder S. Basran, David Bowes, Stephen Harrow, Robert Olson, Suresh Senan, Andrew Warner, David A. Palma, Stewart Gaede
Topics & Concepts
SABR volatility modelMedicineRandomized controlled trialConfidence intervalAdverse effectMalignancySurgeryNuclear medicineInternal medicineMathematicsStochastic volatilityEconometricsVolatility (finance)Prostate Cancer Treatment and ResearchBrain Metastases and TreatmentLung Cancer Diagnosis and Treatment